Following the termination of the applicable waiting period under the HartScottRodino Antitrust Improvements Act of 1976 as amended in April 2021 the Company completed its sale of the PRV and received proceeds of 1020 million with no commission costs which was recorded as a gain from sale of the PRV as it did not have a carrying value at the time of the sale